ATE352295T1 - Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten - Google Patents
Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheitenInfo
- Publication number
- ATE352295T1 ATE352295T1 AT02777571T AT02777571T ATE352295T1 AT E352295 T1 ATE352295 T1 AT E352295T1 AT 02777571 T AT02777571 T AT 02777571T AT 02777571 T AT02777571 T AT 02777571T AT E352295 T1 ATE352295 T1 AT E352295T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- mediated diseases
- cell
- quinazolines
- treat
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0128109.6A GB0128109D0 (en) | 2001-11-23 | 2001-11-23 | Therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE352295T1 true ATE352295T1 (de) | 2007-02-15 |
Family
ID=9926330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02777571T ATE352295T1 (de) | 2001-11-23 | 2002-11-20 | Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7157467B2 (de) |
| EP (1) | EP1453492B1 (de) |
| AT (1) | ATE352295T1 (de) |
| AU (1) | AU2002339194A1 (de) |
| DE (1) | DE60217904T2 (de) |
| GB (1) | GB0128109D0 (de) |
| WO (1) | WO2003045364A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564713B2 (ja) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP1528925B1 (de) * | 2002-07-09 | 2009-04-22 | Astrazeneca AB | Chinazoline derivative und ihre anwendung in der krebsbehandlung |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| ATE395346T1 (de) | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
| JP5739802B2 (ja) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩 |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| JPH11209350A (ja) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| WO2002016352A1 (en) | 2000-08-21 | 2002-02-28 | Astrazeneca Ab | Quinazoline derivatives |
-
2001
- 2001-11-23 GB GBGB0128109.6A patent/GB0128109D0/en not_active Ceased
-
2002
- 2002-11-20 WO PCT/GB2002/005217 patent/WO2003045364A2/en not_active Ceased
- 2002-11-20 AT AT02777571T patent/ATE352295T1/de not_active IP Right Cessation
- 2002-11-20 US US10/496,464 patent/US7157467B2/en not_active Expired - Fee Related
- 2002-11-20 AU AU2002339194A patent/AU2002339194A1/en not_active Abandoned
- 2002-11-20 EP EP02777571A patent/EP1453492B1/de not_active Expired - Lifetime
- 2002-11-20 DE DE60217904T patent/DE60217904T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60217904T2 (de) | 2007-11-15 |
| AU2002339194A8 (en) | 2003-06-10 |
| AU2002339194A1 (en) | 2003-06-10 |
| WO2003045364A3 (en) | 2003-08-28 |
| US7157467B2 (en) | 2007-01-02 |
| DE60217904D1 (de) | 2007-03-15 |
| EP1453492A2 (de) | 2004-09-08 |
| EP1453492B1 (de) | 2007-01-24 |
| US20050014773A1 (en) | 2005-01-20 |
| WO2003045364A2 (en) | 2003-06-05 |
| GB0128109D0 (en) | 2002-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE297733T1 (de) | Quinazolinderivate für die behandlung durch t- zellen vermittelter krankheiten | |
| ATE385238T1 (de) | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände | |
| DE60223262D1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
| DE60135029D1 (de) | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis | |
| DE60329533D1 (de) | Cyclische sulfamide zur inhibierung von gamma-sekretase | |
| DE60121931D1 (de) | Chinazolinverbindungen | |
| DE60219793D1 (de) | Methode zur behandlung von zytokinvermittelten erkrankungen | |
| ATE365551T1 (de) | Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
| GB0226931D0 (en) | Chemical compounds | |
| WO2001042231A3 (en) | Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors | |
| TR200102967T2 (tr) | Substitüsyonlu azollar | |
| DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
| ATE352295T1 (de) | Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten | |
| DE602004005814D1 (de) | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus | |
| ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE148109T1 (de) | Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids | |
| ATE442854T1 (de) | Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| DE69333962D1 (de) | Modifizierte zellen auf der basis des betain-katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| DE60042210D1 (de) | Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit | |
| ATE314066T1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz | |
| DE50207119D1 (de) | 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien | |
| DE50105253D1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |